Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...